ASH 2019 | MRD in CLL: which settings is this most important?
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the use of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL). Dr Woyach highlights how the treatment used impacts the prognostic nature of MRD status. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up